How do you choose among the available PD-1/PDL-1 inhibitors approved for metastatic bladder cancer?

This is an evolving field. While the thought had been all the drugs were likely equivalent in efficacy (with no head to head trials) this has changed in the past week. Roche had a press release in which they announced the Phase III IMvigor211 study that evaluated atezolizumab in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) did not meet its primary endpoint of overall s...

The therapeutic landscape for metastatic and locally-advanced urothelial cancers of the bladder and urinary tract has undergone significant paradigm change in the last few years with the introduction of anti-PD1/PDL1 immune checkpoint inhibitors. To date, five agents are approved by FDA, including anti-PD1 agents nivolumab and pembrolizumab, and anti-PDL1 agents atezolizumab, durvalumab and avelumab in the platinum-refractory setting. Atezolizumab and pembrolizumab have also received FDA approva...